Loading organizations...
nQ Medical develops a digital therapeutics platform focused on the detection and management of neurocognitive and neuromotor disorders. The company’s core product utilizes passive data collection from personal devices, allowing for continuous, unobtrusive monitoring. This approach provides objective and actionable insights into disease progression, aiming to transform how clinicians and patients track and understand neurological conditions outside traditional clinical settings.
The company was co-founded in 2016 by Richie A. Bavasso and Mark Pascarella. Their insight stemmed from the recognition that traditional neurological assessments are often episodic and subjective, missing critical data points in daily life. Bavasso and Pascarella aimed to leverage ubiquitous personal technology to provide a more comprehensive and continuous understanding of neurological health, thereby enabling earlier intervention and more personalized care strategies.
nQ Medical’s platform serves individuals affected by neurocognitive and neuromotor disorders, as well as the healthcare professionals involved in their care. The company’s vision is to establish a new standard for neurological disease management by integrating passive data collection into everyday life. This ongoing surveillance capability seeks to empower both patients and providers with timely, relevant information to optimize treatment decisions and improve long-term outcomes.
nQ Medical has raised $5.0M across 2 funding rounds.
nQ Medical has raised $5.0M in total across 2 funding rounds.
nQ Medical is a computational biotechnology company founded in 2016 out of MIT, specializing in a Digital Biomarker Discovery Platform that uses passive, AI-aided analysis of personal device interactions to phenotype neurological diseases.[1][2][4] It serves patients, clinicians, health systems, and pharmaceutical researchers by enabling early detection (years ahead of traditional tools), granular tracking of disease progression via real-world data (RWD/RWE), and measurement of therapy impacts for conditions like Parkinson's, Alzheimer's/MCI, ALS, Multiple Sclerosis, Long COVID, stroke, and others.[1][2][4] The platform holds FDA Breakthrough Device Designation, with a de novo submission for Parkinson's biomarker completed in March 2022 and clearance expected shortly after; it has evolved into a "NeuroCare" service model partnering with health systems to extend neurology care, alleviate staffing shortages, and reach underserved areas.[1][3]
Growth momentum includes multiple clinical trials (e.g., for PD, AD, MS, ALS, mTBI) yielding promising results on cognitive/motor decline, one filed patent in cognition/motor control, and positive stakeholder reception for applications in trial recruitment, remote monitoring, and virtual care expansion.[1][2][4]
nQ Medical spun out from MIT research in 2016, where four years of clinical trials validated its AI technology for changing neurological disease management.[1][4][6] The core idea emerged from computational analysis of device interactions to detect subclinical symptoms in prodromal stages of neurodegenerative diseases, outperforming biochemical markers in predicting phenoconversion timing.[1] Rather than rushing to market, founders spent two years engaging stakeholders—providers, payers, clinicians, patients, and industry—to refine the value proposition, identifying strong fit for underserved Parkinson's patients who see clinicians infrequently.[4]
Key figures include CEO Richie Bavasso, who highlighted quantitative insights between visits, and Teresa Arroyo-Gallego, associated with AI development for ALS and brain health.[4][7] Pivotal moments: FDA Breakthrough Designation for early-stage Parkinson's/ALS biomarkers, promising AD trial results distinguishing PD/AD symptoms, and the shift to NeuroCare service amid evolving digital medicine models.[1][3][4]
nQ Medical rides the AI-digital health wave in neurology, where passive biomarkers address gaps in traditional diagnostics amid aging populations and rising neurodegenerative burdens (e.g., PD/AD/ALS affecting millions).[1][4] Timing aligns with FDA's push for SaMD (Software as a Medical Device), RWE adoption post-COVID, and telehealth/RPM expansion, especially for rural/underserved access where staffing shortages limit in-person care.[1][3] Market forces like Long COVID's neurological sequelae and demand for precise trial endpoints favor its platform, influencing ecosystems by accelerating research (e.g., cohort building, therapy validation) and enabling health systems to scale brain health beyond hospitals.[1][2][4]
It shapes neurotech by bridging computational biotech with clinical deployment, competing in a field with voice analytics peers but standing out via device-agnostic, subclinical detection.[2]
nQ Medical is poised for commercial acceleration post-FDA clearance, with NeuroCare partnerships driving adoption in health systems and pharma trials amid booming digital neurology demand.[1][3] Trends like AI-RWE integration, multimodal biomarkers, and value-based care will propel growth, potentially expanding to more cross-disorder applications (e.g., CAR-T neurotoxicity) and global RPM. Influence may evolve toward ecosystem enabler, powering virtual neurology platforms and influencing guidelines for early phenoconversion detection—democratizing brain health as its MIT roots promised.[1][4]
nQ Medical has raised $5.0M across 2 funding rounds. Most recently, it raised $3.0M Seed in November 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2019 | $3M Seed | — | DigiTx Partners | Announced |
| Nov 1, 2018 | $2M Seed | — | OCA Ventures | Announced |
nQ Medical has raised $5.0M in total across 2 funding rounds.
nQ Medical's investors include DigiTx Partners, OCA Ventures.
